FLT1 and renal cell carcinoma: In regard to PlGF, the plasma concentrations of this VEGFR-1 ligand have been reported to increase in patients with RCC after treatment with the multi-targeted RTK inhibitor sunitinib, suggesting a correlation with angiogenic rescue and resistance to antiangiogenic therapies [139].